The purpose of this workshop was to bring together the collective experience of many disciplines to discuss and evaluate techniques for the detection of functional estrogenicity. Estrogenicity was first defined as a physiological response to a compound that induced estrus in vivo. The bioassay for induction of estrus developed into a uterotropic assay. The classical tissue response evaluated in this assay was an estrogeninduced increase in wet weight and tissue mass. Tissue response follows a time course of stimulation, including an early phase at 2 to 4 hr, followed by a second later phase. A higher dose of compound generates a stronger response. Weak estrogens exhibit the early response phase, but then the response falls off; however, multiple low doses of weak estrogens mimic the full activity of strong estrogens. A host of chemical and molecular biological factors are involved in the uterotropic response.
Gene Activation
Hormone receptor mechanisms existboth membrane and nuclear receptor pathways-that affect gene regulation and interact with one another. Certain genes are specifically regulated by estrogen acting through the estrogen receptor (ER). These effects appear to be mediated by the interaction of the estrogen/ER complex with estrogen response elements (EREs) in regulatory regions of those genes. For instance, the vitellogenin A2 estrogen-responsive sequence has been cloned and can be used to detect and measure estrogen response. The DNA sequence is closely analogous to the sequence of a glucocorticoid responsive element with four base changes.
Korach's group (1) cloned an estrogenresponsive sequence and inserted it into a reporter gene vector. The construct became an estrogen "inducible promoter" linked to bacterial chloramphenicol acetyltransferase (CAT), which can be detected in a transfected cell to measure estrogen-related gene activity. When an ER-positive target cell such as MCF-7 is transfected with this receptor-specific reporter-gene construct, CAT expression can be measured following estrogen treatment. In a test against a nonresponsive (ER negative) cell, transfection with the receptor-specific reporter alone does not lead to estrogen-induced CAT expression. It must be transfected with ER to get the hormonally induced CAT production, demonstrating that the system is specific for ER-mediated gene expression and regulation. This system will respond to treatment with stilbestrol estrogens with CAT gene expression as well. Phosphoimaging of the CAT gene product can be used for easy quantitation.
Phytoestrogen compounds were tested with this ERE-CAT construct-transfection system. CAT stimulation by genistein, coumestrol, and zearalenone was compared with the stimulation produced by estradiol. CAT The gold standard at this time is still the mouse uterine bioassay, precisely because it replicates a living situation and incorporates the effects of metabolism, serum binding, and pharmacokinetics. However, a complete dose-response assay can be expensive and time consuming; it is also a difficult process for testing a large number of chemicals. In vitro assays may be cheaper, quicker, and more reproducible; however, the difficulties already mentioned must be considered and dealt with to allow their use in exposure studies and possible risk assessments. A question was posed by a number of participants: How do we come up with a way to design the best assays for screening water or other contaminated sources to determine estrogenic activity?
Proliferation Controls
The question that has guided the efforts of Soto's laboratory in the area of proliferation has been how to screen for a variety of chemicals quickly (2) . It is important to remember that environmental contaminants of widely diverse chemical structure mimic estrogen actions. From a public safety concern, estrogenicity should be tested before chemicals are released into the environment.
Screening should be based on the end point of estrogenic action that has the greatest physiological relevance. A crucial end point can be based on the definition of an estrogen promulgated by Roy Hertz in 1985 (3): an estrogen is a substance that can elicit the mitotic stimulation of the tissues of the female genital tract; therefore, measuring cell proliferation is of key importance in assessing estrogenicity. To determine whether chemical "X" is an estrogen, one must test its ability to induce proliferation of estrogen-responsive target cells, even though not all estrogen responses or target tissues respond with proliferation.
The question of whether fish in lake "Y or birds in region "Z" are exposed to estrogenic xenobiotics can be answered at an initial level of screening by examining 3 nM (4) . Approximately 85% of estradiol is bound to plasma proteins in this assay (5) .
Screening for estrogens using males as a model should not be done because estrogens are primarily defined by their ability to increase the mitotic activity of female secondary sex organs. There are reports of effects on male fertility due to exposure to estrogens. In males, estrogens are believed to act via a negative feedback to inhibit gonadotropins; this results in the lowering of androgen production by Leydig cells and inhibition of spermatogenesis.
There is no endogenous estrogen in this assay; we are measuring direct effects. An enzyme inhibitor could be an effector of an estrogen response in a system where there is a source of estrogens, such as in any animal model. Moreover, this assay can be used as a first screen for estrogenicity; any positive response would require further study to determine an underlying mechanism of action.
It was pointed out by McLachlan that in the 1930s CC14 was described as an estrogen because of the enhanced estrogenlike sequelae of CC14 administration. It was later learned that these estrogenlike effects occurred because of CC14 destruction of the liver, which resulted in decreased turnover and an elevation of the level of estradiol in the circulation.
An MCF-7 variant has been modified to grow in serum-free and nonestrogenic medium by Briand et al. (6) . This variant behaves similarly in the E-SCREEN assay when exposed to 10% charcoal-dextran stripped human serum (estradiol [E2] concentration in the medium is below 0.001 pg/ml; this is below 4 fM or about 1/1000 of the dose needed for the smallest significant proliferative response). MCF-7 cells are exposed to practically no estrogen in this "estrogenless" condition.
VFtellogenin as a Biomarker
Could a universal assay for vertebrate vitellogenins be used as a new test for environmental estrogens? Sullivan described a screen that defines an estrogen as something that induces vitellogenesis [Heppell et al., this volume; (7)]. Vitellogenin is a classic steroid-inducible protein; if you expose an oviparous vertebrate to estrogen, it will synthesize VTG. VTG is synthesized in the liver under the control of estrogen. This usually occurs in females but can also be induced in males. VTG is taken up into the oocyte by receptor-mediated endocytosis. It is present in the plasma of females several months before ovulation and is related to cholesterol and mineral transporters. In serum collected from brown bullhead, Sullivan observed a massive induction of a protein in tumor-bearing males and females, which is not present in control females; this induction appeared to be the result of an environmental insult. The induced protein was shown to be VTG by N-terminal amino acid sequencing.
For the purposes of a universal assay, VTG itself is hard to work with since it varies in structure between species. So, the paradigm includes creation of monoclonal antibodies to vertebrate VTG. Sullivan's group screened first for antibodies that recognize both rainbow trout and striped bass VTGs. The second screen was against VTG from fish, amphibians, and mammals. A positive screening result from one clone included cross-reactivity to VTG from bass, perch, trout, tilapia, sturgeon, chicken, tuatara, and platypus; there was a questionable result in this assay for rartlesnake VTG due to a high background.
Antibodies to specific portions of the molecule can be generated. It 
Conclusion
At the end of the presentation and workshop, one of the participants posed two overlying problems. First, if we are concerned about exposure to the male, the critical period is in utero. Second, how does the male fetus protect itself against estrogens, either maternal or from other sources? We have no answer right now. We need an overall picture of how we are exposed to estrogens, and we need a method to determine our exact levels ofexposure.
